PI
ITCI

Putnam Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Putnam Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$14M Buy
195,072
+70,646
+57% +$4.06M 0.02% 279
2023
Q3 		$6.48M Buy
124,426
+16,848
+16% +$982K 0.01% 391
2023
Q2 		$6.81M Buy
+107,578
New +$6.7M 0.01% 392

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments's ITCI Position: Q4 2023 in Review

Putnam Investments increased its Intra-Cellular Therapies Inc. (ITCI) stake by 57% in Q4 2023, buying an estimated $4.06M and bringing the position to 195,072 shares worth $14M. The position accounts for 0.02% of the portfolio, ranked #279.

Putnam Investments first reported a position in ITCI in Q2 2023 and has held it in 3 quarters since. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

  • Putnam Investments held 195,072 shares of Intra-Cellular Therapies Inc. worth $14M as of Q4 2023.
  • Putnam Investments bought 70,646 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $4.06M.
  • Intra-Cellular Therapies Inc. made up 0.02% of Putnam Investments's portfolio in Q4 2023, its #279 holding.
  • Putnam Investments first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and has held it in 3 quarters since.
  • 333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.